Pycnogenol® efficiency on glycaemia, motor nerve conduction velocity and markers of oxidative stress in mild type diabetes in rats

Phytotherapy Research

Volumn 23, Issue 8, 2009, Pages 1169-1174

  Jankyova, S ^a   Kucera, P ^b   Goldenberg, Z ^b   Yaghi, D ^a   Navarova, J ^c   Kyselova, Z ^c   Stolc, S ^c   Klimas, J ^a   Racanska, E ^a   Matyas, S ^a  

^a Physics and Informatics   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

Diabetes; Glycaemia; MNCV; NAGA; Pycnogenol ; TBARs

Indexed keywords

GLUCOSE; N ACETYL BETA GLUCOSAMINIDASE; PYCNOGENOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ACETYLGLUCOSAMINIDASE; FLAVONOID; PYCNOGENOLS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; MALE; MOTOR NERVE CONDUCTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; POSTPRANDIAL STATE; RAT; STREPTOZOCIN DIABETES; WEIGHT CHANGE; ANIMAL; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; NERVE CONDUCTION; WISTAR RAT;

ANIMALIA; RATTUS;

ACETYLGLUCOSAMINIDASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; MALE; NEURAL CONDUCTION; OXIDATIVE STRESS; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 68049098934     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2776     Document Type: Article

References (30)

1. Barrett AJ, Heath MF. 1977. Lysosomal enzymes. In Lysosomes: A Laboratory Handbook, Dingle JT (ed.), 2nd edn. Elsevier/North-Holland Biomedical Press: Amsterdam, 19-145.
2. Berryman AM, Maritim AC, Sanders RA, Watkins III JB. 2004. Influence of treatment of diabetic rats with combinations of pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress. J Biochem Mol Toxicol 18: 345-352.
3. Cameron NE, Cotter MA. 1999. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 45: 137-146.
4. Ceriello A. 2003. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 26: 1589-1596.
5. Chéliout-Héraut F, Zrek N, Khemliche H, Lemaitre A, Martinez M, Bour F. 2008. Small fibers dysfunction in diabetic neuropathy. J Chin Clin Med 3: 68-73.
6. Cumbie BC, Hermayer KL. 2007. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag 3: 823-832.
7. Dobretsov M, Romanovsky D, Stimers JR. 2007. Early diabetic neuropathy: Triggers and mechanisms. World J Gastroenterol 13: 175-191. (Pubitemid 46231321)
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2003. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26(Suppl 1): 5-20.
9. Fraga CG, Leibovitz BF, Topell AL. 1988. Lipid peroxidation measured as TBARS in tissue slices. Characterization and comparison with homogenate and microsomes. Free Radic Biol Med 4: 155-161.
10. Greenberg DA, Jin K. 2005. Neural gene therapy: sensational finding. Gene Ther 12: 1161-1162.
11. Hayden MR, Tyagi S. 2004. Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit 10: RA291-RA307. (Pubitemid 40268569)
12. Inoguchi T, Sonta T, Tsubouchi H et al. 2003. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes role of vascular NAD(P)H oxidase. J Am Nephrol 14: S227-S232. (Pubitemid 36903930)
13. Liu X, Wei J, Tan F, Zhou S, Würthwein G, Rohdewald P. 2004a. Antidiabetic effect of Pycnogenol® French maritime pine bark extract in patients with diabetes type II. Life Sci 75: 2505-2513. (Pubitemid 39195257)
14. Liu X, Zhou HJ, Rohdewald P. 2004b. French maritime pine bark extract pycnogenol dose-dependently lowers glucose in type 2 diabetic patients. Diabetes Care 27: 893-896.
15. Lonn E, Yusuf S, Hoogwerf B et al. 2002. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919-1927. (Pubitemid 41071045)
16. Maritim AC, Dene BA, Sanders RA, Watkins III JB. 2003a. Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 17: 193-199. (Pubitemid 36818195)
17. Maritim AC, Sanders RA, Watkins III JB. 2003b. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17: 24-38. (Pubitemid 36410972)
18. Obrosova IG, van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. 2002. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16: 123-125.
19. Packer L, Rimbach G, Virgili F. 1999. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 27: 704-724. (Pubitemid 29408657)
20. Pari L, Latha M. 2004. Protective role of Scoparia plant extract on brain antioxidant status and lipid peroxidation in STZ diabetic male Wistar rats. BMC Complement Altern Med 4: 16-24. (Pubitemid 39637317)
21. Quine SD, Raghu PS. 2005. Effects of (-)-epicatechin, a flavonoid on lipid peroxidation and antioxidants in streptozotocin-induced diabetic liver, kidney and heart. Pharmacol Rep 57: 610-615.
22. Rohdewald P. 2002. A review of the French maritime pine bark extract (Pycnogenol® ), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 40: 158-168. (Pubitemid 34296383)
23. Sekar D, Sivagnanam K, Subramanian S. 2004. Antidiabetic activity of Momordica charantia seeds on streptozotocin induced diabetic rats. Pharmazie 60: 383-387.
24. Sharma SS, Sayyed SG. 2006. Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy. Clin Exp Pharmacol Physiol 33: 1022-1028.
25. Skalska S, Kyselova Z, Gajdosikova A, Karasu C, Stefek M, Stolc S. 2008. Protective effect of stobadine on ncv in streptozotocin-diabetic rats: augmentation by vitamin E. Accepted in GPB. Gen. Physical. Biophys 27: 106-114.
26. Sotnikova R, Skalska S, Okruhlicova L et al. 2006. Changes in the function and ultrastructure of vessels in the rat model of multiple low dose streptozotocin-induced diabetes. Gen Physiol Biophys 25: 289-302. (Pubitemid 44857442)
27. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. 2004. C-peptide, Na+, K(+)-ATPase, and diabetes. Exp Diabesity Res 5: 37-50.
28. van Dam PS. 2002. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 18: 176-184.
29. Veves A, King GL. 2001. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 107: 1215-1218.
30. Ziegler D, Ametov A, Barinov A et al. 2006. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29: 2365-2370. (Pubitemid 44912237)